CN Patent

CN116768857B — Ezh2/hdac双靶点抑制剂及其制备方法和医药用途

Assigned to China Pharmaceutical University · Expires 2026-03-20 · 0y expired

What this patent protects

本发明公开了EZH2/HDAC双靶点抑制剂及其制备方法和医药用途。包含结构如通式(Ⅰ)‑(V)所示的化合物或其药学上可接受的盐，其中，R选自C 5 ‑C 9 烷基，羰基烷烃链，苄基，嘧啶环，不饱和五元杂环。本发明提供了一种新型的靶向EZH2/HDAC双靶点抑制剂，本发明所公示化合物能够有效的靶向EZH2和HDAC，可作为血液瘤以及其他癌症的有效治疗剂。

USPTO Abstract

本发明公开了EZH2/HDAC双靶点抑制剂及其制备方法和医药用途。包含结构如通式(Ⅰ)‑(V)所示的化合物或其药学上可接受的盐，其中，R选自C 5 ‑C 9 烷基，羰基烷烃链，苄基，嘧啶环，不饱和五元杂环。本发明提供了一种新型的靶向EZH2/HDAC双靶点抑制剂，本发明所公示化合物能够有效的靶向EZH2和HDAC，可作为血液瘤以及其他癌症的有效治疗剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN116768857B
Jurisdiction
CN
Classification
—
Expires
2026-03-20
Drug substance claim
No
Drug product claim
No
Assignee
China Pharmaceutical University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.